APOE*3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome

Diabetes, Obesity and Metabolism

Volumn 16, Issue 6, 2014, Pages 537-544

  van den Hoek, Anita M ^a   van der Hoorn, J W A ^a   Maas, A C ^a   van den Hoogen, R M ^a   van Nieuwkoop, A ^a   Droog, S ^a   Offerman, E H ^a   Pieterman, E J ^a   Havekes, L M ^a,b   Princen, H M G ^a  

^a TNO   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Diabetic dyslipidemia; Insulin resistance; NAFLD; Obesity; Pharmacological treatment

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1 INHIBITOR; ANTIDIABETIC AGENT; ATORVASTATIN; CHOLESTEROL ESTER; FENOFIBRATE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LIRAGLUTIDE; NICOTINIC ACID; ROSIGLITAZONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; 11BETA HYDROXYSTEROID DEHYDROGENASE 1; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTILIPEMIC AGENT; APOLIPOPROTEIN E3; APOLIPOPROTEIN E3 (LEIDEIN); CETP PROTEIN, HUMAN; CHOLESTEROL ESTER TRANSFER PROTEIN; GLUCAGON LIKE PEPTIDE 1; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DYSLIPIDEMIA; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIPID LIVER LEVEL; MALE; METABOLIC SYNDROME X; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; TRANSGENIC MOUSE; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; GENETICS; HUMAN; NON-ALCOHOLIC FATTY LIVER DISEASE;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ANIMALS; APOLIPOPROTEIN E3; CHOLESTEROL ESTER TRANSFER PROTEINS; DISEASE MODELS, ANIMAL; FENOFIBRATE; GLUCAGON-LIKE PEPTIDE 1; HEPTANOIC ACIDS; HUMANS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; MALE; METABOLIC SYNDROME X; MICE, TRANSGENIC; NIACIN; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; PYRROLES; THIAZOLIDINEDIONES;

EID: 84899619481     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12252     Document Type: Article

References (47)

1. Reilly MP, Rader DJ. The metabolic syndrome: more than the sum of its parts? Circulation 2003; 108(1524-4539; 0009-7322): 1546-1551.
2. Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. Cell 2004; 116(0092-8674; 0092-8674): 337-350.
3. Varga O, Harangi M, Olsson IA, Hansen AK. Contribution of animal models to the understanding of the metabolic syndrome: a systematic overview. Obes Rev 2010; 11(1467-789; 1467-7881): 792-807.
4. Kennedy AJ, Ellacott KL, King VL, Hasty AH. Mouse models of the metabolic syndrome. Dis Model Mech 2010; 3(1754-8411; 1754-8403): 156-166.
5. Brindley DN, Russell JC. Animal models of insulin resistance and cardiovascular disease: some therapeutic approaches using JCR:LA-cp rat. Diabetes Obes Metab 2002; 4(1462-8902; 1462-8902): 1-10.
6. Hiraoka-Yamamoto J, Nara Y, Yasui N, Onobayashi Y, Tsuchikura S, Ikeda K. Establishment of a new animal model of metabolic syndrome: SHRSP fatty (fa/fa) rats. Clin Exp Pharmacol Physiol 2004; 31(0305-1870; 0305-1870): 107-109.
7. Lamont BJ, Drucker DJ. Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed mice. Diabetes 2008; 57: 190-198.
8. Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, Herz J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 1993; 92(0021-9738; 0021-9738): 883-893.
9. Zhang SH, Reddick RL, Burkey B, Maeda N. Diet-induced atherosclerosis in mice heterozygous and homozygous for apolipoprotein E gene disruption. J Clin Invest 1994; 94(0021-9738; 0021-9738): 937-945.
10. Rigotti A, Trigatti BL, Penman M, Rayburn H, Herz J, Krieger M. A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism. Proc Natl Acad Sci U S A 1997; 94(0027-8424; 0027-8424): 12610-12615.
11. Zuckerman SH, Evans GF, Schelm JA, Eacho PI, Sandusky G. Estrogen-mediated increases in LDL cholesterol and foam cell-containing lesions in human ApoB100xCETP transgenic mice. Arterioscler Thromb Vasc Biol 1999; 19: 1476-1483.
12. Hansen MK, McVey MJ, White RF et al. Selective CETP inhibition and PPARalpha agonism increase HDL cholesterol and reduce LDL cholesterol in human ApoB100/human CETP transgenic mice. J Cardiovasc Pharmacol Ther 2010; 15: 196-202.
13. Briand F. The use of dyslipidemic hamsters to evaluate drug-induced alterations in reverse cholesterol transport. Curr Opin Investig Drugs 2010; 11: 289-297.
14. Westerterp M, van der Hoogt CC, de Haan W et al. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice. Arterioscler Thromb Vasc Biol 2006; 26: 2552-2559.
15. Zadelaar S, Kleemann R, Verschuren L et al. Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol 2007; 27: 1706-1721.
16. Kleemann R, Princen HM, Emeis JJ et al. Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin. Circulation 2003; 108: 1368-1374.
17. Delsing DJ, Offerman EH, van Duyvenvoorde W et al. Acyl-CoA:cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE*3-Leiden mice. Circulation 2001; 103: 1778-1786.
18. van der Hoorn JW, Kleemann R, Havekes LM, Kooistra T, Princen HM, Jukema JW. Olmesartan and pravastatin additively reduce development of atherosclerosis in APOE*3Leiden transgenic mice. J Hypertens 2007; 25: 2454-2462.
19. Kooistra T, Verschuren L, de Vries-van der Weij J et al. Fenofibrate reduces atherogenesis in ApoE*3Leiden mice: evidence for multiple antiatherogenic effects besides lowering plasma cholesterol. Arterioscler Thromb Vasc Biol 2006; 26: 2322-2330.
20. Jiang XC, Agellon LB, Walsh A, Breslow JL, Tall A. Dietary cholesterol increases transcription of the human cholesteryl ester transfer protein gene in transgenic mice. Dependence on natural flanking sequences. J Clin Invest 1992; 90(0021-9738; 0021-9738): 1290-1295.
21. van der Hoogt CC, de Haan W, Westerterp M et al. Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression. J Lipid Res 2007; 48(0022-2275; 0022-2275): 1763-1771.
22. van der Hoorn JW, de Haan W, Berbee JF et al. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice. Arterioscler Thromb Vasc Biol 2008; 28(1524-4636; 1079-5642): 2016-2022.
23. de Haan W, de Vries-Van der W, van der Hoorn JW et al. Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin. Circulation 2008; 117(1524-4539; 0009-7322): 2515-2522.
24. van den Maagdenberg AM, Hofker MH, Krimpenfort PJ et al. Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia. J Biol Chem 1993; 268(0021-9258; 0021-9258): 10540-10545.
25. de Knijff P, van den Maagdenberg AM, Stalenhoef AF et al. Familial dysbetalipoproteinemia associated with apolipoprotein E3-Leiden in an extended multigeneration pedigree. J Clin Invest 1991; 88: 643-655.
26. Muurling M, Jong MC, Mensink RP et al. A low-fat diet has a higher potential than energy restriction to improve high-fat diet-induced insulin resistance in mice. Metabolism 2002; 51: 695-701.
27. Hayek T, Ito Y, Azrolan N et al. Dietary fat increases high density lipoprotein (HDL) levels both by increasing the transport rates and decreasing the fractional catabolic rates of HDL cholesterol ester and apolipoprotein (Apo) A-I. Presentation of a new animal model and mechanistic studies in human Apo A-I transgenic and control mice. J Clin Invest 1993; 91: 1665-1671.
28. Mensink RP, Zock PL, Kester AD, Katan MB. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr 2003; 77: 1146-1155.
29. Kodama S, Saito K, Tanaka S et al. Influence of fat and carbohydrate proportions on the metabolic profile in patients with type 2 diabetes: a meta-analysis. Diabetes Care 2009; 32: 959-965.
30. Le KA, Tappy L. Metabolic effects of fructose. Curr Opin Clin Nutr Metab Care 2006; 9: 469-475.
31. Tada Y, Kagota S, Matsumoto M et al. Characterization of cardiac size and function in SHRSP.Z-Lepr(fa)/IzmDmcr rats, a new animal model of metabolic syndrome. Biol Pharm Bull 2010; 33: 1971-1976.
32. Noda K, Melhorn MI, Zandi S et al. An animal model of spontaneous metabolic syndrome: Nile grass rat. FASEB J 2010; 24: 2443-2453.
33. Walder K, Oakes N, Fahey RP, Cooney G, Zimmet PZ, Collier GR. Profile of dyslipidemia in Psammomys obesus, an animal model of the metabolic syndrome. Endocr Regul 2002; 36: 1-8.
34. Briand F, Thieblemont Q, Burcelin R, Sulpice T. Sitagliptin promotes macrophage-to-faeces reverse cholesterol transport through reduced intestinal cholesterol absorption in obese insulin resistant CETP-apoB100 transgenic mice. Diabetes Obes Metab 2012; 14: 662-665.
35. Briand F, Thieblemont Q, Muzotte E, Sulpice T. High-fat and fructose intake induces insulin resistance, dyslipidemia, and liver steatosis and alters in vivo macrophage-to-feces reverse cholesterol transport in hamsters. J Nutr 2012; 142: 704-709.
36. Tiikkainen M, Hakkinen AM, Korsheninnikova E, Nyman T, Makimattila S, Yki-Jarvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004; 53: 2169-2176.
37. Davies MJ, Kela R, Khunti K. Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes. Diabetes Obes Metab 2011; 13: 207-220.
38. Bolen S, Feldman L, Vassy J et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007; 147: 386-399.
39. Goldberg RB, Kendall DM, Deeg MA et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28: 1547-1554.
40. Raskin P, Rendell M, Riddle MC et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001; 24: 1226-1232.
41. Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
42. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497(0098-7484 (Print); 0098-7484 (Linking)).
43. Carlson LA, Oro L. Effect of treatment with nicotinic acid for one month on serum lipids in patients with different types of hyperlipidemia. Atherosclerosis 1973; 18: 1-9.
44. Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005; 45: 185-197.
45. Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: a systematic review. JAMA 2007; 298: 786-798.
46. Rosenstock J, Banarer S, Fonseca VA et al. The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. Diabetes Care 2010; 33: 1516-1522.
47. Feig PU, Shah S, Hermanowski-Vosatka A et al. Effects of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome. Diabetes Obes Metab 2011; 13: 498-504.